CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 165 enrolled
Drug / intervention
Telcagepant +3 moredrug
Likely dose
Telcagepant 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00662818
NCT00662818Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Placebo- and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of Acute Migraine in Patients With Stable Vascular Disease

Merck Sharp & Dohme LLC·interventional·Posted Apr 21, 2008·Updated Oct 19, 2018

In Brief

A Phase 3 clinical trial evaluating Telcagepant, Acetaminophen/Paracetamol, and 2 other interventions for Migraine Disorders and 5 related conditions. Completed, enrolled 165 participants.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders, Heart Disease, Cerebrovascular Accident, TIA (Transient Ischemic Attack), Vascular Diseases, Peripheral Vascular Diseases
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 21, 2008
Enrollment StartMar 17, 2008
Primary CompletionSep 2, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.2 years ago

Interventions

Telcagepantdrug

Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)

Acetaminophen/Paracetamoldrug

Acetaminophen/Paracetamol (500 mg X 2 dosage units)

Placebo to Telcagepantdrug

Placebo 300 mg soft gel capsules or placebo 280 mg tablet.

Placebo to Acetaminophen/Paracetamoldrug

Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)